Together these observations suggest that CDK9 inhibition might be effective in high CDK9-expressing TNBCs as it exhibits antineoplastic effects in tumor cells and additionally disrupts tumor-initiating CSLCs. This evidence concerns the gene CDK9 and neoplasm.